350
Participants
Start Date
September 13, 2022
Primary Completion Date
November 15, 2026
Study Completion Date
November 15, 2026
Non interventional study
CLL patients initiated with acalabrutinib at their physician's discretion between January 1, 2021 and December 31, 2022 . Secondary data collection
Research Site, Aix-en-Provence
Research Site, Amiens
Research Site, Angers
Research Site, Ars-Laquenexy
Research Site, Avignon
Research Site, Besançon
Research Site, Béziers
Research Site, Bobigny
Research Site, Bourg-en-Bresse
Research Site, Brest
Research Site, Caen
Research Site, Cahors
Research Site, Carcassonne
Research Site, Cesson-Sévigné
Research Site, Chalon-sur-Saône
Research Site, Chambéry
Research Site, Clamart
Research Site, Clermont-Ferrand
Research Site, Corbeil-Essonnes
Research Site, Dunkirk
Research Site, Essey-lès-Nancy
Research Site, Grenoble
Research Site, La Chaussée-Saint-Victor
Research Site, La Tronche
Research Site, LE Chesnay-rocquencourt
Research Site, Le Kremlin-Bicêtre
Research Site, Le Mans
Research Site, Le Puy-en-Velay
Research Site, Lens
Research Site, Libourne
Research Site, Lille
Research Site, Limoges
Research Site, Lorient
Research Site, Marseille
Research Site, Meaux
Research Site, Melun
Research Site, Mont-de-Marsan
Research Site, Nantes
Research Site, Nevers
Research Site, Nîmes
Research Site, Orléans
Research Site, Paris
Research Site, Perpignan
Research Site, Pessac
Research Site, Périgueux
Research Site, Pontoise
Research Site, Reims
Research Site, Rennes
Research Site, Roubaix
Research Site, Rouen
Research Site, Saumur
Research Site, Tarbes
Research Site, Toulouse
Research Site, Tours
Research Site, Trévenans
Research Site, Troyes
Research Site, Valence
Research Site, Vandœuvre-lès-Nancy
Research Site, Vantoux
Research Site, Vesoul
Research Site, Vichy
Lead Sponsor
AstraZeneca
INDUSTRY